Filing Flows

Filing Flows › Companies › Tela Bio › Cash flow

Tela Bio cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$9.4M in Q2 2026 · −$31.6M over twelve months

Operating cash flow−$9.4M
Capital spending−$59K
Free cash flow−$9.4M
Cash conversion cycle189 days

Analysis

In Q2 2026, Tela Bio generated −$9.4M of operating cash flow and spent $59K on capital projects, leaving free cash flow of −$9.4M. That is $1.4M less than in Q2 2025 (−$8.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$31.1M; the largest uses were operating cash flow ($31.1M), capital spending ($480K), taxes on employees’ shares ($119K); besides operations, cash came from other financing ($25.6M), asset & business sales ($1.4M); the cash balance fell by $4.6M.

Operating cash flow was −$9.4M against net income of −$11.3M. The largest differences: accrued liabilities +$1.3M, payables −$1.0M, inventory +$862K.

Its cash conversion cycle was 189 days (receivables 46 + inventory 202 − payables 59).

Free cash flow

Tela Bio: free cash flow by quarterTela Bio: free cash flow by quarter−$9.1MQ3 2024−$7.8MQ4 2024−$9.8MQ1 2025−$8.0MQ2 2025−$5.9MQ3 2025−$5.0MQ4 2025−$11.3MQ1 2026−$9.4MQ2 2026
Operating cash flow less capital spending.
Tela Bio: operating cash flow against capital spendingTela Bio: operating cash flow against capital spendingOperating cash flowCapital spending−$9.0M$122KQ3 2024−$7.5M$264KQ4 2024−$9.7M$32KQ1 2025−$7.9M$114KQ2 2025−$5.7M$211KQ3 2025−$4.9M$91KQ4 2025−$11.2M$119KQ1 2026−$9.4M$59KQ2 2026
Latest (Q2 2026): Operating cash flow −$9.4M, Capital spending $59K.

Capital allocation, year by year

Tela Bio: where the cash came from (up) and went (down), by fiscal yearTela Bio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$30.4MFY2021: Shares issued $547KFY2021: Capital spending −$627K$547KFY2021FY2022: Operating cash flow −$40.7MFY2022: Net borrowing $10.0MFY2022: Shares issued $34.4MFY2022: Capital spending −$872K$44.4MFY2022FY2023: Operating cash flow −$40.9MFY2023: Shares issued $46.5MFY2023: Asset sales $12KFY2023: Capital spending −$611K$46.5MFY2023FY2024: Operating cash flow −$41.6MFY2024: Shares issued $226KFY2024: Asset sales $5.4MFY2024: Capital spending −$989K$5.7MFY2024FY2025: Operating cash flow −$28.2MFY2025: Net borrowing −$42.4MFY2025: Shares issued $1KFY2025: Asset sales $1.3MFY2025: Capital spending −$448K$1.3MFY2025
Over these 5 years operating cash flow totalled −$182M; the largest uses were operating cash flow ($182M) and net borrowing ($42.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$30.4M
Debt$41.4M
Net debt$11.0M
Due within a year$3.3M
Cash runway12 months

Tela Bio is burning cash: its operations consume cash, a free cash flow of −$31.6M a year at the current rate against $30.4M of cash and investments: a runway of about 12 months; $3.3M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Tela Bio: sources (+) and uses (−) of cash, Q2 2026Tela Bio: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$9.4MCash drawn (+) / kept (−)$9.2MAsset & business sales$298KCapital spending−$59KTaxes on employees’ shares−$15KExchange rates−$10K
Tela Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Tela Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$31.1MOther financing$25.6MCash drawn (+) / kept (−)$4.6MAsset & business sales$1.4MCapital spending−$480KTaxes on employees’ shares−$119KShares issued$72KExchange rates$33K

From profit to cash

Tela Bio: net income to operating cash flow, Q2 2026Tela Bio: net income to operating cash flow, Q2 2026Net income−$11.3MDepreciation & amortization$171KStock-based pay$613KReceivables$89KInventory$862KPayables−$1.0MAccrued liabilities$1.3MPrepaid and other assets−$838KOperating cash flow−$9.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20264620259189
Q1 20264716243166
Q4 20254814831165
Q3 20255015929181
Q2 20254918944194
Q1 20255020047204
Q4 20245619234214
Q3 20244920737219

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$9.4M−$59K—$9.2M−$9.4M
Q1 2026−$11.2M−$119K$1K$11.3M−$11.3M
Q4 2025−$4.9M−$91K—−$21.1M−$5.0M
Q3 2025−$5.7M−$211K—$5.3M−$5.9M
Q2 2025−$7.9M−$114K—$7.9M−$8.0M
Q1 2025−$9.7M−$32K$1K$9.8M−$9.8M
Q4 2024−$7.5M−$264K—−$35.4M−$7.8M
Q3 2024−$9.0M−$122K—$9.2M−$9.1M

Tela Bio: income statement and cash flow

Tela Bio, Q2 2026: revenue $19.3M (-4% year over year), operating margin -48.1%. The chart follows the revenue to costs, profit and cash.

Tela Bio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.